Melane Sampson, Author at BioTuesdays

Developments

Zomedica partners with SIRE to expand sales into Central America

Zomedica (NYSEA:ZOM) announced the expansion of its sales reach into Costa Rica through a partnership with SIRE Veterinario, which will be the exclusive distributor of Zomedica products in that country. “Our...

August 14, 2024

Developments

FDA accepts scPharmaceuticals sNDA to expand heart failure drug indication

scPharmaceuticals (NASDAQ:SCPH) has announced FDA approval of its supplemental NDA (sNDA) for FUROSCIX, expanding its indication to New York Heart Association (NYHA) Class IV chronic heart failure patients. Previously...

August 12, 2024

Developments

Awakn screens first patient in Phase 3 trial of treatment for AUD

Awakn Life Sciences (CSE:AWKN; OTCQB:AWKNF; FSE:954) has announced that the first patient has been screened in its landmark MORE-KARE Phase 3 trial of AWKN-001, an investigational, novel medication-assisted treatment...

August 9, 2024

Developments

Veru meets full enrollment target in Phase 2b study of Enobosarm for Obesity

Veru (NASDAQ:VERU) announced that it has reached its targeted full enrollment of 150 patients for its Phase 2b QUALITY clinical trial of enobosarm, in combination with semaglutide, aimed at muscle preservation for high...

August 8, 2024

Developments

Rockwell launches ergonomic hemodialysis packaging solution for home patients and acute facilities

Rockwell Medical (NASDAQ:RMTI) announced the launch of a convenience pack including pre-mixed containers of the company’s hemodialysis concentrate products, offering in-home dialysis patients and acute dialysis...

August 8, 2024

Developments

89bio names Francis Sarena as COO

89Bio (NASDAQ:ETNB) announced the appointment of Francis Sarena as chief operating officer, effective August 5, 2024. Mr. Sarena brings 25 years of biotech industry experience to his new role at 89bio. Prior to joining...

August 7, 2024

Developments

Silo partners with global CRO for preclinical study to advance homing peptide in MS

Silo Pharma (NASDAQ:SILO) has entered into an agreement with WuXi AppTec for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). Silo Pharma is...

August 7, 2024

Developments

Quoin Pharma plans clinical study of peeling skin syndrome in children

Quoin Pharmaceuticals (NASDAQ:QNRX) announced plans to initiate an investigator-led clinical study to evaluate the safety and efficacy of QRX003 in pediatric patients with peeling skin syndrome (PSS). The study will be...

August 6, 2024

Developments

Abivax achieves key enrollment milestone in Phase 3 trial of Obefazimod in UC

Abivax SA (Euronext Paris, NASDAQ:ABVX) reports reaching the 600-patient enrollment milestone for its Phase 3 ABTECT trial to evaluate its lead investigational drug candidate, Obefazimod, in patients with moderate-to...

August 6, 2024

Executive Moves

Carisma Therapeutics expands SAB with renowned KOLs

Carisma Therapeutics (NASDAQ:CARM) has appointed Drs. Scott Friedman and Ira Tabas to its scientific advisory board (SAB). “It is an honor to welcome Dr. Friedman and Dr. Tabas to our SAB,” said Steven...

August 6, 2024

Author - Melane Sampson

Zomedica partners with SIRE to expand sales into Central America

FDA accepts scPharmaceuticals sNDA to expand heart failure drug indication

Awakn screens first patient in Phase 3 trial of treatment for AUD

Veru meets full enrollment target in Phase 2b study of Enobosarm for Obesity

Rockwell launches ergonomic hemodialysis packaging solution for home patients and acute facilities

89bio names Francis Sarena as COO

Silo partners with global CRO for preclinical study to advance homing peptide in MS

Quoin Pharma plans clinical study of peeling skin syndrome in children

Abivax achieves key enrollment milestone in Phase 3 trial of Obefazimod in UC

Carisma Therapeutics expands SAB with renowned KOLs

General

More